视网膜生技药品市场规模、份额、成长分析，按药物类别、按适应症、按分销管道、按地区 - 行业预测，2025 年至 2032 年

预计 2023 年全球视网膜生技药品市场规模将达到 229 亿美元，并从 2024 年的 246.4 亿美元成长到 2032 年的 442.7 亿美元，预测期内（2025-2032 年）的复合年增长率为 7.6%。

视网膜疾病，尤其老龄化黄斑部病变(AMD)、糖尿病视网膜病变和视网膜静脉阻塞的盛行率不断上升，是人口老化面临的迫切问题。生物技术的进步正在刺激对创新治疗方法的需求，特别是在视网膜生技药品领域，基因和细胞疗法越来越受欢迎。抗盲基金会和美国黄斑部病变基金会等着名组织正在提高公众意识并支持重要的研究倡议。受医疗基础设施改善和糖尿病盛行率上升的推动，新兴市场，尤其是中国、巴西和印度，将经历显着成长。总体而言，由于治疗的进步、认识的提高以及全球对抗这些疾病的努力，视网膜生技药品市场预计将扩大。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步
• 贸易分析
• 客户和购买标准分析

视网膜生技药品市场规模（依药物类别）

• 市场概况
• VEGF-A 拮抗剂
• TNF-α 抑制剂

视网膜生技药品市场规模（依适应症划分）

• 市场概况
• 黄斑部病变
• 糖尿病黄斑部水肿
• 糖尿病视网膜病变
• 葡萄膜炎
• 其他的

视网膜生技药品市场规模（依分销管道划分）

• 市场概况
• 机构投资人销售
• 零售药局
• 通讯药房
• 零售

视网膜生技药品市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• F. Hoffmann-La Roche Ltd（Switzerland）
• Regeneron Pharmaceuticals Inc.（USA）
• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Amgen Inc.（USA）
• Johnson & Johnson（USA）
• Biogen Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bristol-Myers Squibb Company（USA）
• Sanofi Genzyme（France）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Bausch & Lomb Incorporated（USA）
• Adverum Biotechnologies, Inc.（USA）
• MeiraGTx Holdings plc（UK）
• Oxurion NV（Belgium）
• Kodiak Sciences Inc.（USA）
• Clearside Biomedical, Inc.（USA）
• Neurotech Pharmaceuticals, Inc.（USA）
• Opthea Limited（Australia）

结论和建议

Global Retinal Biologics Market size was valued at USD 22.9 billion in 2023 and is poised to grow from USD 24.64 billion in 2024 to USD 44.27 billion by 2032, growing at a CAGR of 7.6% during the forecast period (2025-2032).

The increasing prevalence of retinal diseases, notably age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion, is a pressing concern driven by aging populations. Advances in biotechnology have catalyzed demand for innovative treatment options, particularly in retinal biologics, where gene therapy and cell-based therapies are gaining traction. Notable organizations, including the Foundation Fighting Blindness and the American Macular Degeneration Foundation, are enhancing public awareness and supporting critical research initiatives. Emerging markets, especially in countries like China, Brazil, and India, are poised for significant growth, fueled by improved healthcare infrastructure and rising diabetes rates. Overall, the retinal biologics market is primed for expansion, driven by advancements in treatment, increasing awareness, and a concerted global effort to address these conditions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Biologics Market Segmental Analysis

Global Retinal Biologics Market is segmented by Drug Class, Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into VEGF-A Antagonists and TNF-a Inhibitors. Based on Indication, the market is segmented into Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Uveitis and Others. Based on Distribution Channel, the market is segmented into Institutional Sales, Retail Pharmacies, Mail Order Pharmacies and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Biologics Market

One of the primary drivers of the Global Retinal Biologics market is the alarming rise in vision-related issues, particularly in the United States. According to data from the Centers for Disease Control and Prevention, millions are diagnosed with diabetic retinopathy, with many at risk of developing further complications that could severely affect their eyesight. The increasing incidence of this condition is expected to boost the demand for effective treatments, thereby propelling significant growth in the market. As a result, the escalating need for retinal biologics is anticipated to create a robust pathway for advancements and investment in this sector.

Restraints in the Global Retinal Biologics Market

One of the significant restraints in the Global Retinal Biologics market is the high cost associated with these therapies. These biologic drugs can be prohibitively expensive, limiting access for individuals in developing countries who struggle to afford them. Additionally, the complexity involved in the manufacturing and commercialization of retinal biologics, coupled with stringent regulatory requirements, poses further challenges. This combination of factors not only restricts the market potential but also creates barriers for patients needing these crucial treatments, ultimately hindering overall market growth and accessibility to life-changing therapies for those in need around the world.

Market Trends of the Global Retinal Biologics Market

The Global Retinal Biologics market is witnessing a significant trend towards genetic treatment approaches, driven by recent advancements in gene therapy research for retinal diseases, particularly inherited retinal dystrophies. These innovative therapies are transforming the landscape of retinal biologic drugs, offering targeted solutions that address the root causes of these conditions rather than just alleviating symptoms. As a result, the market is expected to experience robust growth, fueled by increasing investments in R&D, promising clinical trial outcomes, and a rising awareness of genetic therapies among patients and healthcare professionals. This shift underscores a broader movement towards personalized medicine in ophthalmology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis
• Customer & Buying Criteria Analysis

Global Retinal Biologics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• VEGF-A Antagonists
• TNF-a Inhibitors

Global Retinal Biologics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Macular Degeneration
• Diabetic Macular Edema
• Diabetic Retinopathy
• Uveitis
• Others

Global Retinal Biologics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Institutional Sales
• Retail Pharmacies
• Mail Order Pharmacies
• Retail Sales

Global Retinal Biologics Market Size & CAGR (2025-2032)

• North America (Drug Class, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Genzyme (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch & Lomb Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx Holdings plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurotech Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Opthea Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations